Japan approves Veltassa® for adult hyperkalemia treatment, offering a new option for management.

Veltassa® (patiromer) has received approval in Japan for treating adults with hyperkalemia, a condition characterized by elevated potassium levels in the blood. This approval marks a significant advancement in the management of this condition, providing a new treatment option for affected individuals.

September 24, 2024
3 Articles

Further Reading